Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295

被引：0
|
作者：
Adra, Nabil
Hauke, Ralph J.
Kaimakliotis, Hristos Z.
Gulati, Shuchi
Hashemi, Neda
Pili, Roberto
机构：
[1] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Nebraska Canc Specialists, Omaha, NE USA
[3] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[4] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
[5] Univ New Mexico, Albuquerque, NM 87131 USA
[6] Roswell Park Canc Inst, Buffalo, NY 14263 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS587
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study
    Li, Y.
    Zhou, A.
    Liu, S.
    He, M.
    Chen, K-N.
    Tian, Z.
    Chen, H.
    Tian, H.
    Yu, Y.
    Qu, W.
    Xue, L.
    Wang, S.
    Bie, F.
    Zhou, B.
    Huang, H. Y.
    Fang, Y.
    Li, B.
    Dai, X.
    Gao, S.
    He, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1101 - S1101
  • [32] Neoadjuvant chemotherapy combined with PD-1 inhibitor for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II clinical trial.
    Sun, Yan
    Zhao, Dan
    Zhang, Bin
    Gao, Shunyu
    Liu, Wei
    Xiao, Shaowen
    Zheng, Baomin
    Huang, Zhou
    Bai, Yanhua
    Wang, Tianxiao
    Liu, Weixin
    Xu, Xiaolong
    Wang, Nan
    Zhang, Yaru
    Wan, Meng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
    Salous, Tareq
    Shukla, Nikhil A. A.
    Althouse, Sandra K. K.
    Perkins, Susan M. M.
    Furqan, Muhammad
    Leal, Ticiana
    Traynor, Anne M. M.
    Feldman, Lawrence E. E.
    Hanna, Nasser H. H.
    Durm, Greg A. A.
    CANCER, 2023, 129 (02) : 264 - 271
  • [34] Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial
    McGregor, Bradley
    O'Donnell, Peter H.
    Balar, Arjun
    Petrylak, Daniel
    Rosenberg, Jonathan
    Yu, Evan Y.
    Quinn, David, I
    Heath, Elisabeth, I
    Campbell, Mary
    Hepp, Zsolt
    McKay, Caroline
    Steinberg, Joyce
    Regnault, Antoine
    Mazerolle, Flora
    Galsky, Matthew D.
    EUROPEAN UROLOGY, 2022, 81 (05) : 515 - 522
  • [35] Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
    Tan, Zhichao
    Wu, Yan
    Fan, Zhengfu
    Gao, Tian
    Guo, Wei
    Bai, Chujie
    Xue, Ruifeng
    Li, Shu
    Zhang, Lu
    Wang, Xinyu
    Jia, Ling
    Liu, Jiayong
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5577 - 5583
  • [36] Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trialA randomized clinical trial of neoadjuvant therapy for ESCC
    Yong Li
    Aiping Zhou
    Shuoyan Liu
    Ming He
    Keneng Chen
    Ziqiang Tian
    Yin Li
    Jianjun Qin
    Zhen Wang
    Haiquan Chen
    Hui Tian
    Yue Yu
    Wang Qu
    Liyan Xue
    Shun He
    Shuhang Wang
    Fenglong Bie
    Guangyu Bai
    Bolun Zhou
    Zhaoyang Yang
    Huiyao Huang
    Yan Fang
    Benjamin Li
    Xiangrong Dai
    Shugeng Gao
    Jie He
    BMC Medicine, 21
  • [37] TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
    Tagawa, Scott T.
    Petrylak, Daniel Peter
    Grivas, Petros
    Agarwal, Neeraj
    Sternberg, Cora N.
    Hernandez, Chris
    Siemon-Hryczyk, Peggy
    Goswami, Trishna
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
    Tagawa, Scott T.
    Petrylak, Daniel Peter
    Grivas, Petros
    Agarwal, Neeraj
    Sternberg, Cora N.
    Siemon-Hryczyk, Peggy
    Goswam, Trishna
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [39] Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Lee, Chung-Han
    Shah, Amishi Y.
    Makker, Vicky
    Taylor, Matthew
    Shaffer, David
    Hseih, James J.
    Cohn, Allen L.
    Di Simone, Chris
    Marin, Alvaro Pinto
    Rasco, Drew
    Gunnestad-Ribe, Sara
    Richards, Donald A.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Wu, Jane
    Schmidt, Emmett V.
    Perini, Rodolfo
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 101 - 102
  • [40] Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
    Azaro Pedrazzoli, A. B.
    Moreno, V.
    Gomez-Roca, C. A.
    Even, C.
    Cassier, P.
    Hernandez Guerrero, T. C.
    de Miguel, M.
    Korakis, I.
    Purcea, D.
    Roy, E.
    Gollmer, K.
    Riff, C.
    Szyldergemajn, S. A.
    Calvo, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S483 - S483
12345